Levi & Korsinsky is investigating the Board of Directors of Sagent Pharmaceuticals, Inc. (NASDAQ: SGNT) in connection with the sale of the Company to Nichi-Iko Pharmaceutical Co., Ltd. Under the terms of the transaction, Sagent shareholders will receive $21.75 for each share of Sagent stock they own.
The investigation concerns whether the Board of Sagent breached their fiduciary duties to stockholders by failing to adequately shop the Company before agreeing to enter into this transaction, and whether Nichi-Iko Pharmaceutical Co., Ltd. is underpaying for Sagent shares. In particular, at least one analyst has set a price target of $25.00 per Sagent share.
To receive more information, please fill out the form.